Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval

The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval. 

World Health Day. Global Health Awareness Concept. Globe and Stethoscope on blue background.
The Chikungunya Vaccine was assessed under the EMA’s OPEN framework to promote global public health • Source: Shutterstock

The European Medicines Agency has recommended granting pan-EU marketing approval to 14 new products, including Valneva’s chikungunya vaccine Ixchiq and Pfizer/Spark Therapeutics’ hemophilia B gene therapy Durveqtix (fidanacogene elaparvovec).

If approved, Ixchiq will become the first vaccine in the EU to protect adults 18 years and older against chikungunya....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography